Literature DB >> 8344705

UVB irradiation renders corneal allografts tolerogenic for allospecific delayed hypersensitivity responses.

J Y Niederkorn1, E Mayhew.   

Abstract

Heterotopic corneal allografts treated with ultraviolet (UV) radiation not only failed to elicit allospecific delayed-type hypersensitivity (DTH) responses in mice but rendered the hosts tolerant to subsequent immunization with normally immunogenic corneal allografts. The immunological tolerance induced by UV-treated grafts was cyclophosphamide sensitive and antigen specific. Adoptive transfer studies revealed that the tolerance to donor alloantigens could be transferred with CD4+, CD8- T cells which suppressed alloimmune DTH responses at the afferent but not the efferent limb. The capacity of UV-treated corneal allografts to induce allospecific tolerance was related to UV irradiation and not simply a result of loss of corneal viability. Formalin-fixed corneal allografts could not produce similar tolerization for DTH responses. Selective debridement of either the corneal epithelium or endothelium revealed that the corneal endothelium was the critical layer necessary for UV-dependent tolerance induction. Furthermore, the initial exposure to UV irradiation must occur through the endothelium and not the epithelium. Thus, the single-cell layered corneal endothelium is the target for the immunomodulatory effects of UV irradiation on corneal allografts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8344705      PMCID: PMC1421873     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Prevention of the induction of allospecific cytotoxic T lymphocyte and delayed-type hypersensitivity responses by ultraviolet irradiation of corneal allografts.

Authors:  J Y Niederkorn; D Callanan; J R Ross
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

2.  Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB.

Authors:  G B Toews; P R Bergstresser; J W Streilein
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

3.  Antigen presentation by murine epidermal langerhans cells and its alteration by ultraviolet B light.

Authors:  G Stingl; L A Gazze-Stingl; W Aberer; K Wolff
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

4.  Regulation of delayed-type hypersensitivity. III. Effect of cyclophosphamide on the suppressor cells for delayed-type hypersensitivity to sheep erythrocytes in mice.

Authors:  H K Gill; F Y Liew
Journal:  Eur J Immunol       Date:  1978-03       Impact factor: 5.532

5.  Relationship between epidermal Langerhans cell density ATPase activity and the induction of contact hypersensitivity.

Authors:  D H Lynch; M F Gurish; R A Daynes
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

6.  In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.

Authors:  J L Benson; J Y Niederkorn
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

7.  Heterotopic corneal grafting in mice: a new approach to the study of corneal alloimmunity.

Authors:  J W Streilein; J McCulley; J Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-10       Impact factor: 4.799

8.  Delayed type hypersensitivity to allogeneic cells in mice. I. Requirements for optimal sensitization and definition of the response.

Authors:  F Smith; J F Miller
Journal:  Int Arch Allergy Appl Immunol       Date:  1979

9.  Tolerance or hypersensitivity to 2,4-dinitro-1-fluorobenzene: the role of Langerhans cell density within epidermis.

Authors:  J W Streilein; G T Toews; J N Gilliam; P R Bergstresser
Journal:  J Invest Dermatol       Date:  1980-05       Impact factor: 8.551

10.  Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.

Authors:  M Röllinghoff; A Starzinski-Powitz; K Pfizenmaier; H Wagner
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.